Benefit and risk evaluation of quinapril hydrochloride-Reference-Cited by-同舟云学术

Benefit and risk evaluation of quinapril hydrochloride

Published:2023-04-03 Issue:4 Volume:22 Page:271-277
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Barkhordarian Maryam¹,Lawrence Jannel A.²,Ulusan Sebahat³,Erbay Muhammed Ibrahim⁴,Aronow Wilbert S.⁵,Gupta Rahul⁶^ORCID

Affiliation:

1. Department of Internal Medicine, Hackensack Meridian Health - Palisades Medical Center, North Bergen, NJ, USA

2. Department of Internal Medicine, Ross University School of Medicine, Largo, MD, USA

3. Department of Internal Medicine, Suleyman Demirel University School of Medicine, Isparta, Turkey

4. Cerrahpasa School of Medicine Istanbul, Istanbul University Cerrahpasa, Istanbul, Turkey

5. Department of Cardiology, Westchester Medical Center, New York, NY, USA

6. Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2203481

Reference62 articles.

1. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 54891, Quinapril hydrochloride; [cited 2022 Nov. 10]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Quinapril-hydrochloride.

2. Overall Tolerance and Safety of Quinapril in Clinical Trials

3. Clinical Pharmacology of Quinapril in Healthy Volunteers and in Patients with Hypertension and Congestive Heart Failure

4. Quinapril: A Double-Blind, Placebo-Controlled Trial in Essential Hypertension

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Evaluation of Biological Activities for a Novel 1,2,3,4-Tetrahydroisoquinoline Conjugate with Dipeptide Derivatives: Insights from Molecular Docking and Molecular Dynamics Simulations;ACS Omega;2023-12-12